Mirum Pharmaceuticals Stock Price, News & Analysis

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announced on September 10-11, 2022, the granting of inducement awards to 11 new employees, comprising 47,750 stock options and 23,900 restricted stock units (RSUs). The stock options have an exercise price of $25.15, equal to the closing price on September 9, 2022, and will vest over four years. The RSUs will vest over three years. This award follows Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to support the company's growth in treating rare diseases.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced its participation in key investor conferences, including Citi's 17th Annual BioPharma Conference on September 7, 2022, H.C. Wainwright's Global Investment Conference on September 12-13, 2022, and Baird's Global Healthcare Conference on September 14, 2022. The company focuses on rare and orphan diseases, notably with its approved treatment LIVMARLI® for Alagille syndrome. Mirum is also advancing its pipeline with investigational therapies targeting debilitating liver diseases, including ongoing clinical trials for pediatric and adult conditions.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has closed its underwritten public offering of 4,000,000 shares of common stock at $23.00 per share, raising gross proceeds of $92 million. The offering included full exercise of underwriters' options for an additional 521,739 shares. This was conducted under an effective shelf registration statement filed with the SEC. Mirum focuses on developing therapies for rare liver diseases, with its approved medication LIVMARLI® and investigational treatments for various liver conditions.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announced on August 10, 2022 that it granted inducement awards of non-qualified stock options for 28,250 shares and 14,100 RSUs to eight new employees. Each stock option has an exercise price of $24.93 per share, the closing price on the grant date, and will vest over four years. The RSUs will vest over three years. These awards comply with Nasdaq Listing Rule 5635(c)(4) and are part of Mirum’s 2020 Inducement Plan. Mirum focuses on rare diseases, offering LIVMARLI for Alagille syndrome and has investigational treatments for other liver diseases.

Mirum Pharmaceuticals announced the pricing of its underwritten public offering, consisting of 3,478,261 shares at $23.00 each, aiming for gross proceeds of $80 million. Underwriters have a 30-day option to buy an additional 521,739 shares. The offering's closure is expected on August 12, 2022. J.P. Morgan, SVB Securities, and Evercore ISI are the joint managers for this offering, which is under a previously filed shelf registration statement. Mirum focuses on developing therapies for rare liver diseases, with products like LIVMARLI and ongoing clinical trials.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has initiated an underwritten public offering to raise $80.0 million in common stock, with an option for underwriters to purchase an additional $12.0 million. The offering follows a shelf registration statement declared effective by the SEC on August 12, 2020. J.P. Morgan, SVB Securities, and Evercore ISI are leading the offering, but no assurance is given regarding its completion or terms. Mirum is known for its focus on treatments for rare liver diseases, including the approved LIVMARLI® and ongoing clinical trials for various conditions.

Mirum Pharmaceuticals reported a net product sales figure of $17.5 million for LIVMARLI in Q2 2022, bringing year-to-date sales to $28.4 million. While total operating expenses rose slightly to $48.9 million, R&D expenses decreased to $25.4 million. The company recorded a net loss of $26.9 million, a reduction from $43.9 million in Q2 2021. Anticipated milestones include EMA approval for Alagille syndrome and Phase 3 data for PFIC trials later this year. A conference call for further updates is scheduled for August 4, 2022.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is set to report its second quarter financial results on August 4, 2022, at 4:30 p.m. ET. The company will host a conference call to discuss its progress and priorities for 2022. Mirum’s pipeline includes treatments for rare liver diseases, with its approved drug, LIVMARLI®, targeting cholestatic pruritus in Alagille syndrome patients. The company is also advancing several investigational treatments, including volixibat for primary sclerosing cholangitis and ongoing clinical trials for pediatric liver diseases.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announced on July 8, 2022, the grant of stock options and restricted stock units (RSUs) totaling 64,500 shares to seven new employees under its 2020 Inducement Plan. The stock options have an exercise price of $23.86 per share, vesting over four years, while the RSUs will vest over three years. This is part of the company's strategy to attract talent amidst its growth in developing treatments for rare diseases, including its approved drug LIVMARLI® and investigational treatments for liver diseases.